Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Spac backtrack confirms that the gene therapy bubble has burst
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.